cn3
Monday, 12 December 2016
Changes but No Clarity at Alexion
A rare disease biotech investigation still has unanswered questions for Alexion Pharmaceuticals.
from WSJ.com: Markets http://ift.tt/2gsOYzw
via https://ifttt.com/ IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment